Differences in Therapeutic Responses and Factors Affecting Post-Stroke Depression at a Later Stage According to Baseline Depression
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Eun-Jae | - |
dc.contributor.author | Kim, Jong S. | - |
dc.contributor.author | Chang, Dae-Il | - |
dc.contributor.author | Park, Jong-Ho | - |
dc.contributor.author | Ahn, Seong Hwan | - |
dc.contributor.author | Cha, Jae-Kwan | - |
dc.contributor.author | Heo, Ji Hoe | - |
dc.contributor.author | Sohn, Sung-Il | - |
dc.contributor.author | Lee, Byung-Chul | - |
dc.contributor.author | Kim, Dong-Eog | - |
dc.contributor.author | Kim, Hahn Young | - |
dc.contributor.author | Kim, Seongheon | - |
dc.contributor.author | Kwon, Do-Young | - |
dc.contributor.author | Kim, Jei | - |
dc.contributor.author | Seo, Woo-Keun | - |
dc.contributor.author | Lee, Jun | - |
dc.contributor.author | Park, Sang-Won | - |
dc.contributor.author | Koh, Seong-Ho | - |
dc.contributor.author | Kim, Jin Young | - |
dc.contributor.author | Choi-Kwon, Smi | - |
dc.contributor.author | Kim, Min-Sun | - |
dc.contributor.author | Lee, Ji Sung | - |
dc.date.accessioned | 2021-09-02T11:41:42Z | - |
dc.date.available | 2021-09-02T11:41:42Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2018-05 | - |
dc.identifier.issn | 2287-6391 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/75591 | - |
dc.description.abstract | Background and Purpose The pathophysiology of post-stroke depression (PSD) is complex and may differ according to an individual's mood immediately after stroke. Here, we compared the therapeutic response and clinical characteristics of PSD at a later stage between patients with and without depression immediately after stroke. Methods This study involved a post hoc analysis of data from EMOTION (ClinicalTrials.gov NCT01278498), a placebo-controlled, double-blind trial that examined the efficacy of escitalopram (10 mg/day) on PSD and other emotional disturbances among 478 patients with acute stroke. Participants were classified into the Baseline-Blue (patients with baseline depression at the time of randomization, defined per the Montgomery-Asberg Depression Rating Scale [MADRS]>= 8) or the Baseline-Pink groups (patients without baseline depression). We compared the efficacy of escitalopram and predictors of 3-month PSD (MADRS >=) between these groups. Results There were 203 Baseline-Pink and 275 Baseline-Blue patients. The efficacy of escitalopram in reducing PSD risk was more pronounced in the Baseline-Pink than in the Baseline-Blue group (P for interaction=0.058). Several risk factors differentially affected PSD development based on the presence of baseline depression (P for interaction <0.10). Cognitive dysfunction was an independent predictor of PSD in the Baseline-Blue, but not in the Baseline-Pink group, whereas the non-use of escitalopram and being female were more strongly associated with PSD in the Baseline-Pink group. Conclusions Responses to escitalopram and predictors of PSD 3 months following stroke differed based on the presence of baseline depression. Our data suggest that PSD pathophysiology is heterogeneous; therefore, different therapeutic strategies may be needed to prevent PSD emergence following stroke. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN STROKE SOC | - |
dc.subject | ACUTE CEREBRAL INFARCTION | - |
dc.subject | EMOTIONAL INCONTINENCE | - |
dc.subject | SEX-DIFFERENCES | - |
dc.subject | MAJOR DEPRESSION | - |
dc.subject | LESION LOCATION | - |
dc.subject | STROKE PATIENTS | - |
dc.subject | FOLLOW-UP | - |
dc.subject | ESCITALOPRAM | - |
dc.subject | PREDICTORS | - |
dc.subject | SYMPTOMS | - |
dc.title | Differences in Therapeutic Responses and Factors Affecting Post-Stroke Depression at a Later Stage According to Baseline Depression | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kwon, Do-Young | - |
dc.identifier.doi | 10.5853/jos.2017.02712 | - |
dc.identifier.scopusid | 2-s2.0-85047899809 | - |
dc.identifier.wosid | 000436119300011 | - |
dc.identifier.bibliographicCitation | JOURNAL OF STROKE, v.20, no.2, pp.258 - + | - |
dc.relation.isPartOf | JOURNAL OF STROKE | - |
dc.citation.title | JOURNAL OF STROKE | - |
dc.citation.volume | 20 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 258 | - |
dc.citation.endPage | + | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002351450 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.subject.keywordPlus | ACUTE CEREBRAL INFARCTION | - |
dc.subject.keywordPlus | EMOTIONAL INCONTINENCE | - |
dc.subject.keywordPlus | SEX-DIFFERENCES | - |
dc.subject.keywordPlus | MAJOR DEPRESSION | - |
dc.subject.keywordPlus | LESION LOCATION | - |
dc.subject.keywordPlus | STROKE PATIENTS | - |
dc.subject.keywordPlus | FOLLOW-UP | - |
dc.subject.keywordPlus | ESCITALOPRAM | - |
dc.subject.keywordPlus | PREDICTORS | - |
dc.subject.keywordPlus | SYMPTOMS | - |
dc.subject.keywordAuthor | Depression | - |
dc.subject.keywordAuthor | Stroke | - |
dc.subject.keywordAuthor | Escitalopram | - |
dc.subject.keywordAuthor | Anger | - |
dc.subject.keywordAuthor | Emotional incontinence | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.